ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay

Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature.
- The concentrations of the 10 proteins (A1AT; apolipoprotein E-APOE; angiogenin-ANG; carbonic anhydrase 9-CA9; interleukin 8-IL-8; matrix metalloproteinase 9-MMP-9; matrix metalloproteinase 10-MMP10; plasminogen activator inhibitor 1-PAI-1; syndecan-SDC1; and vascular endothelial growth factor-VEGF) were monitored using two prototype multiplex array platforms and an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s technical specifications.
- The range for detecting each biomarker was improved in the multiplex assays, even though the lower limit of quantification (LLOQ) was typically lower in the commercial ELISA kits. The area under the receiver operating characteristics (AUROC) of the prototype multiplex assays was reported to be 0.97 for the multiplex bead-based immunoassay (MBA) and 0.86 for the multiplex electrochemoluminescent assay (MEA).
- The sensitivities and specificities for MBA were 0.93 and 0.95, respectively, and for MEA were 0.85 and 0.80, respectively. Accuracy, positive predictive values (PPV), and negative predictive values (NPV) for MBA were 0.94, 0.95, and 0.93, respectively, and for MEA were 0.83, 0.81, and 0.84, respectively. Based on these encouraging preliminary data, we believe that a multiplex protein array is a viable platform that can be utilized as an efficient and highly accurate tool to quantitate multiple proteins within biologic specimens.

PSMB8 antibody |
|||
70R-19589 | Fitzgerald | 50 ul | EUR 522 |
Description: Rabbit polyclonal PSMB8 antibody |
PSMB8 Antibody |
|||
1-CSB-PA116429 | Cusabio |
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100 |
PSMB8 Antibody |
|||
1-CSB-PA018886GA01HU | Cusabio |
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF |
PSMB8 Antibody |
|||
1-CSB-PA018886LA01HU | Cusabio |
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
PSMB8 Antibody |
|||
1-CSB-PA775839 | Cusabio |
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:2000-1:5000, WB:1:500-1:2000, IHC:1:25-1:100 |
PSMB8 Antibody |
|||
E94054 | EnoGene | 100μg | EUR 255 |
Description: Available in various conjugation types. |
PSMB8 Antibody |
|||
E97340 | EnoGene | 100ul | EUR 255 |
Description: Available in various conjugation types. |
PSMB8 Antibody |
|||
E043134 | EnoGene | 100μg/100μl | EUR 255 |
Description: Available in various conjugation types. |
PSMB8 Antibody |
|||
E314816 | EnoGene | 100ug/200ul | EUR 295 |
Description: Available in various conjugation types. |
PSMB8 Conjugated Antibody |
|||
C43134 | SAB | 100ul | EUR 476.4 |
PSMB8 Polyclonal Antibody |
|||
A73468 | EpiGentek |
|
|
PSMB8 Antibody, HRP conjugated |
|||
1-CSB-PA018886LB01HU | Cusabio |
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
PSMB8 Antibody, FITC conjugated |
|||
1-CSB-PA018886LC01HU | Cusabio |
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
PSMB8 Antibody, Biotin conjugated |
|||
1-CSB-PA018886LD01HU | Cusabio |
|
|
Description: A polyclonal antibody against PSMB8. Recognizes PSMB8 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
Monoclonal PSMB8 Antibody, Clone: 1A5 |
|||
AMM02864G | Leading Biology | 0.1ml | EUR 633.6 |
Description: A Monoclonal antibody against Human PSMB8. The antibodies are raised in Mouse and are from clone 1A5. This antibody is applicable in WB and IHC, ICC, E |
Mouse Monoclonal Antibody to PSMB8 |
|||
E10-30255 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
Psmb8/ Rat Psmb8 ELISA Kit |
|||
ELI-15652r | Lifescience Market | 96 Tests | EUR 1063.2 |
PSMB8 |
|||
E8EM1709-54 | EnoGene | 100ul | EUR 275 |
Description: Available in various conjugation types. |
PSMB8 |
|||
enz-670 | ProSpec Tany | 5µg | EUR 60 |
Description: Recombinant Human Proteasome Subunit Beta Type 8 |
Proteasome subunit beta type-8 (PSMB8) Antibody |
|||
20-abx211178 | Abbexa |
|
|
Proteasome subunit beta type-8 (PSMB8) Antibody |
|||
20-abx211851 | Abbexa |
|
|
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
20-abx141396 | Abbexa |
|
|
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
20-abx114776 | Abbexa |
|
|
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
abx028154-400ul | Abbexa | 400 ul | EUR 627.6 |
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
abx028154-80l | Abbexa | 80 µl | EUR 343.2 |
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
20-abx006453 | Abbexa |
|
|
Proteasome Subunit Beta Type-8 (PSMB8) Antibody |
|||
abx011689-100ul | Abbexa | 100 ul | EUR 493.2 |
Monoclonal PSMB8 Antibody (monoclonal) (M01), Clone: 1B3 |
|||
AMM03954G | Leading Biology | 0.1mg | EUR 580.8 |
Description: A Monoclonal antibody against Human PSMB8 (monoclonal) (M01). The antibodies are raised in Mouse and are from clone 1B3. This antibody is applicable in WB, IHC and IF, IP, E |
PSMB8 siRNA |
|||
20-abx930156 | Abbexa |
|
|
PSMB8 siRNA |
|||
20-abx930157 | Abbexa |
|
|
PSMB8 siRNA |
|||
20-abx904317 | Abbexa |
|
|
PSMB8 Rabbit pAb |
|||
A7340-100ul | Abclonal | 100 ul | EUR 369.6 |
PSMB8 Rabbit pAb |
|||
A7340-200ul | Abclonal | 200 ul | EUR 550.8 |
PSMB8 Rabbit pAb |
|||
A7340-20ul | Abclonal | 20 ul | EUR 219.6 |
PSMB8 Rabbit pAb |
|||
A7340-50ul | Abclonal | 50 ul | EUR 267.6 |
PSMB8 Rabbit pAb |
|||
E2507340 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
PSMB8 Blocking Peptide |
|||
BF0434-BP | Affbiotech | 1mg | EUR 234 |
PSMB8/LMP7 Mouse mAb |
|||
E2220606 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
PSMB8 protein (His tag) |
|||
80R-2608 | Fitzgerald | 100 ug | EUR 386.4 |
Description: Purified recombinant PSMB8 protein |
PSMB8 / LMP7 Rabbit pAb |
|||
E2382339 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
Canine PSMB8 ELISA KIT |
|||
ELI-15651d | Lifescience Market | 96 Tests | EUR 1113.6 |
Rat PSMB8 shRNA Plasmid |
|||
20-abx984734 | Abbexa |
|
|
Human PSMB8 shRNA Plasmid |
|||
20-abx953843 | Abbexa |
|
|
Mouse PSMB8 shRNA Plasmid |
|||
20-abx971337 | Abbexa |
|
|
PSMB8 Recombinant Protein (Rat) |
|||
RP222629 | ABM | 100 ug | Ask for price |
PSMB8 Recombinant Protein (Mouse) |
|||
RP165287 | ABM | 100 ug | Ask for price |
PSMB8 Recombinant Protein (Human) |
|||
RP085356 | ABM | 100 ug | Ask for price |
Psmb8 ORF Vector (Rat) (pORF) |
|||
ORF074211 | ABM | 1.0 ug DNA | EUR 607.2 |
PSMB8 ORF Vector (Human) (pORF) |
|||
ORF028453 | ABM | 1.0 ug DNA | EUR 486 |
Psmb8 ORF Vector (Mouse) (pORF) |
|||
ORF055097 | ABM | 1.0 ug DNA | EUR 607.2 |
[KO Validated] PSMB8 Rabbit pAb |
|||
A19933-100ul | Abclonal | 100 ul | EUR 492 |
[KO Validated] PSMB8 Rabbit pAb |
|||
A19933-200ul | Abclonal | 200 ul | EUR 685.2 |
[KO Validated] PSMB8 Rabbit pAb |
|||
A19933-20ul | Abclonal | 20 ul | EUR 265.2 |
[KO Validated] PSMB8 Rabbit pAb |
|||
A19933-50ul | Abclonal | 50 ul | EUR 344.4 |
PSMB8 ELISA Kit (Dog) (OKEH03975) |
|||
OKEH03975 | Aviva Systems Biology | 96 Wells | EUR 1012.8 |
Description: Description of target: ;Species reactivity: Dog;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.064 ng/mL |
PSMB8 ELISA Kit (Human) (OKEH07770) |
|||
OKEH07770 | Aviva Systems Biology | 96 Wells | EUR 1310.4 |
Description: Description of target: The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit.;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.06ng/mL |
PSMB8 ELISA Kit (Human) (OKCD02695) |
|||
OKCD02695 | Aviva Systems Biology | 96 Wells | EUR 950.4 |
Description: Description of target: The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Acts as a major component of interferon gamma-induced sensitivity. Plays a key role in apoptosis via the degradation of the apoptotic inhibitor MCL1. May be involved in the inflammatory response pathway. In cancer cells, substitution of isoform 1 (E2) by isoform 2 (E1) results in immunoproteasome deficiency. Required for the differentiation of preadipocytes into adipocytes.;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.117 ng/mL |
Human PSMB8 Protein Lysate 20ug |
|||
IHUPSMB8PLLY20UG | Innovative research | each | EUR 213 |
Description: Human PSMB8 Protein Lysate 20ug |
Proteasome 20S LMP7/PSMB8 Rabbit mAb |
|||
A23378 | Abclonal | 200μL | EUR 323.7 |
Description: A synthetic peptide corresponding to a sequence within amino acids 864-963 of human ApoER2/LRP8 (Q14114). |
Psmb8 sgRNA CRISPR Lentivector set (Rat) |
|||
K6921501 | ABM | 3 x 1.0 ug | EUR 406.8 |
PSMB8 sgRNA CRISPR Lentivector set (Human) |
|||
K1740301 | ABM | 3 x 1.0 ug | EUR 406.8 |
Psmb8 sgRNA CRISPR Lentivector set (Mouse) |
|||
K4425601 | ABM | 3 x 1.0 ug | EUR 406.8 |
Psmb8 3'UTR GFP Stable Cell Line |
|||
TU266964 | ABM | 1.0 ml | Ask for price |
Psmb8 3'UTR GFP Stable Cell Line |
|||
TU167173 | ABM | 1.0 ml | Ask for price |
PSMB8 3'UTR GFP Stable Cell Line |
|||
TU069046 | ABM | 1.0 ml | EUR 1672.8 |
Rabbit Anti Human PSMB8 Monoclonal Clone AEFI-16 |
|||
IRBAHUPSMB8AEFI16C100UL | Innovative research | each | EUR 496 |
Description: Rabbit Anti Human PSMB8 Monoclonal Clone AEFI-16 |
PSMB8 Protein Vector (Rat) (pPM-C-HA) |
|||
PV296844 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Rat) (pPB-C-His) |
|||
PV296842 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Rat) (pPB-N-His) |
|||
PV296843 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Rat) (pPM-C-His) |
|||
PV296845 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Human) (pPM-C-HA) |
|||
PV113812 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Mouse) (pPM-C-HA) |
|||
PV220388 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Human) (pPB-C-His) |
|||
PV113810 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Human) (pPB-N-His) |
|||
PV113811 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Human) (pPM-C-His) |
|||
PV113813 | ABM | 500 ng | EUR 662.4 |
PSMB8 Protein Vector (Mouse) (pPB-C-His) |
|||
PV220386 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Mouse) (pPB-N-His) |
|||
PV220387 | ABM | 500 ng | EUR 723.6 |
PSMB8 Protein Vector (Mouse) (pPM-C-His) |
|||
PV220389 | ABM | 500 ng | EUR 723.6 |
Psmb8 3'UTR Luciferase Stable Cell Line |
|||
TU216964 | ABM | 1.0 ml | Ask for price |
Comparison of Rapid Anti-HCV Multi-sure Kit with Gold Standard ELISA.
To compare the diagnostic yield of Multi-sure rapid HCV (hepatitis C virus) kit with ELISA.Comparative study.Pakistan Health Research Council, specialised research center for gastroenterology and hepatology, from August 2016 to January 2017.A modified rapid anti-HCV kit was compared with ELISA. This rapid kit is multi-parameter qualitative immune chromatographic kit for the in-vitro detection of antibodies to HCV in human blood.
- Patients who came to PHRC, were tested using anti-HCV ELISA, and their test was run simultaneously on multi-sure HCV rapid kit were included in the study. Each positive and negative sample was included in this study. SPSS software was adapted for data analysis.A total of 420 samples were collected.
- Among them, 255 (61%) were of male and 165 (39%) were of female patients. Mean age was 35 ± 14.33 years. All the samples run for anti-HCV on ELISA were also run on multi-sure rapid kit. It is evident that 22.4% were reactive on ELISA and 23.6% were reactive on rapid kit, while 75.5% were non-reactive on ELISA and 68.1% were non-reactive on rapid kit.
- Borderline positive results were seen in 2.1% on ELISA and 5.0% on rapid kit. Sensitivity of rapid kit was 87.2%, specificity 89.3% with 82.8% positive predictive value and 98.9% negative predictive value.Multi-sure kit showed significantly, less non-reactive and more borderline results as compared to ELISA.
- Comparison of multi-sure rapid kit with ELISA showed that core antibody can be used as an alternate marker for ELISA. Other non-structural proteins including NS3, NS4 and NS5 were found to be less significant. So, it is concluded that this rapid kit may not be recommended as an alternative of ELISA, except for places where ELISA is not available.
Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits.
There are many studies presenting data of biologics and several ELISA kits commercially available for monitoring infliximab serum trough levels (s-IFXt) and anti-drug antibodies (ADAb). We propose to compare technical characteristics and results of three different assays on a cohort of 35 patients under infliximab (IFX) and suffering from inflammatory bowel disease (IBD).s-IFXt and ADAb were systematically measured with three ELISA kits: Lisa-Tracker® Duo infliximab (Theradiag®), Ridascreen® IFX Monitoring (R-Biopharm AG®) and Promonitor® IFX (Progenika Biopharma SA®).
The main technical features that differed between kits for measuring s-IFXt were: (i) TNF coating, (ii) immune complexes revelation strategy and/or (iii) interference with other anti-TNFα agents. For kits measuring ADAb, they were revelation steps and unit of results.
There was an excellent mathematical correlation of s-IFXt between assays however Bland-Altman analysis denoted (i) s-IFXt were on average 48 to 69% higher in Ridascreen® than in the other two assays, and (ii) elevated s-IFXt were higher with Promonitor® compared to Lisa-Tracker®.
As a consequence, there were some substantial discrepancies between assays for classification of s-IFXt into concentration ranges. Despite unstandardized units, pairwise qualitative comparison showed a perfect agreement between the three pairs of ADAb assays.
Our data show that the evaluated assays are not quantitatively interchangeable due to substantial variations in some results that could lead, for some patients, to divergent therapeutic decisions. We remind to be cautious when comparing study results issued from different kits and recommend using the same assay for the longitudinal follow-up of IBD patients